Table 2. . Differentially expressed miRNA associated with blood lead, bone lead or toenail mercury (p < 0.05)†.
| Biomarker | miRNA | Adjusted beta (95% CI) | Interpreted beta as % expression change (95% CI) | p-value | q-value | Predicted targets (n) |
|---|---|---|---|---|---|---|
| Blood lead (n = 60) | hsa-miR-297 | 0.88 (0.21–1.55) | 84.0 (15.7–192.8) | 0.01 | 0.45 | 38 |
| |
hsa-miR-188 |
0.57 (0.11–1.03) |
48.5 (7.9–104.2) |
0.01 |
0.45 |
40 |
| Patella lead (n = 44) | hsa-miR-320e | -0.07 (-0.11 to -0.02) | -4.7 (-7.3 to -1.4) | 0.003 | 0.17 | 64 |
| hsa-miR-22–3p | -0.07 (-0.13 to -0.01) | -4.7 (-8.6 to -0.7) | 0.020 | 0.23 | 597 | |
| hsa-miR-93–5p | -0.10 (-0.19 to -0.01) | -6.7 (-12.3 to -0.7) | 0.025 | 0.23 | 1235 | |
| hsa-miR-769–5p | -0.08 (-0.15 to -0.01) | -5.4 (-9.9 to -0.7) | 0.030 | 0.23 | 82 | |
| hsa-miR-297 | 0.03 (0.00–0.06) | 2.1 (0.0–4.2) | 0.031 | 0.23 | 38 | |
| hsa-miR-425–5p | -0.10 (-0.19–0.00) | -6.7 (-12.3–0.0) | 0.046 | 0.23 | 238 | |
| |
hsa-miR-361–3p |
0.04 (0.00–0.08) |
2.8 (0.0–5.7) |
0.047 |
0.23 |
539 |
| Tibia lead (n = 45) | hsa-miR-575 | -0.06 (-0.1 to -0.02) | -4.1 (-6.7 to -1.4) | 0.003 | 0.08 | 82 |
| hsa-miR-4286 | -0.13 (-0.21 to -0.05) | -8.6 (-13.5 to -3.4) | 0.003 | 0.08 | 227 | |
| hsa-miR-15a-5p | 0.10 (0.02–0.19) | 7.2 (1.4–14.1) | 0.018 | 0.36 | 1452 | |
| hsa-miR-142–3p | 0.08 (0.01–0.16) | 5.7 (0.7–11.7) | 0.029 | 0.40 | 368 | |
| hsa-miR-193b-3p | -0.11 (-0.20 to -0.01) | -7.3 (-12.9 to -0.7) | 0.033 | 0.40 | 340 | |
| |
hsa-miR-494 |
-0.06 (-0.12–0.00) |
-4.1 (-8.0–0.0) |
0.044 |
0.46 |
581 |
| Toenail mercury (n = 40) | hsa-miR-205–5p | -4.03 (-6.48 to -1.58) | -93.9 (-98.9 to -66.6) | 0.001 | 0.02 | 426 |
| hsa-miR-125b-5p | -5.86 (-9.59 to -2.14) | -98.3 (-99.9 to -77.3) | 0.002 | 0.02 | 985 | |
| hsa-let-7b-5p | -2.90 (-4.85 to -0.94) | -86.6 (-96.5 to -47.9) | 0.004 | 0.02 | 1180‡ | |
| hsa-miR-200c-3p | -3.52 (-5.97 to -1.08) | -91.3 (-98.4 to -52.7) | 0.005 | 0.02 | 1074‡ | |
| hsa-miR-342–3p | -3.10 (-5.39 to -0.81) | -88.3 (-97.6 to -43.0) | 0.008 | 0.03 | 337 | |
| hsa-miR-203 | -3.39 (-5.95 to -0.83) | -90.5 (-98.4 to -43.7) | 0.009 | 0.03 | 870 | |
| hsa-let-7a-5p | -4.21 (-7.42 to -0.99) | -94.6 (-99.4 to -49.7) | 0.010 | 0.03 | 1180‡ | |
| hsa-miR-24–3p | -3.79 (-6.99 to -0.60) | -92.8 (-99.2 to -34.0) | 0.020 | 0.05 | 741 | |
| hsa-miR-22–3p | -2.81 (-5.21 to -0.41) | -85.7 (-97.3 to -24.7) | 0.022 | 0.05 | 597 | |
| hsa-miR-23b-3p | -4.14 (-7.76 to -0.52) | -94.3 (-99.5 to -30.3) | 0.025 | 0.05 | 1172‡ | |
| hsa-miR-375 | -2.29 (-4.32 to -0.25) | -79.6 (-95.0 to -15.9) | 0.027 | 0.05 | 233 | |
| hsa-miR-23a-3p | -3.50 (-6.64 to -0.37) | -91.2 (-99.0 to -22.6) | 0.028 | 0.05 | 1172‡ | |
| hsa-miR-210 | -3.77 (-7.20 to -0.34) | -92.7 (-99.3 to -21.0) | 0.031 | 0.05 | 78 | |
| hsa-miR-200b-3p | -3.33 (-6.40 to -0.26) | -90.1 (-98.8 to -16.5) | 0.034 | 0.05 | 1074‡ | |
| hsa-miR-99a-5p | -3.55 (-6.89 to -0.20) | -91.5 (-99.2 to -12.9) | 0.038 | 0.05 | 73 | |
| hsa-miR-21–5p | -5.17 (-10.20 to -0.14) | -97.2 (-99.9 to -9.2) | 0.044 | 0.05 | 340 | |
| hsa-miR-193b-3p | -3.77 (-7.53 to -0.01) | -92.7 (-99.5 to -0.7) | 0.050 | 0.06 | 340 |
Each multivariable regression model was adjusted for maternal age, education, smoke exposure in the home and parity.
†The adjusted beta values represent the fold-change in miRNA per tenfold increase in toenail mercury and blood lead, or per one unit increase for bone lead measures.
‡Let-7b and let-7a, miR-23a and miR-23b, and miR-200b and miR-200c share sequence homology and have identical target mRNAs.